Bloomberg Businessweek

Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People

Watch Carol and Tim LIVE every day on YouTube: <a data-destination="rte:bind" href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>. Bloomberg News Health Care Reporter Madison Muller discusses that patients taking Eli Lilly’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity. Hosts: Tim Stenovec and Katie Greifeld. Producer: Paul Brennan. See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.